<DOC>
	<DOCNO>NCT02953184</DOCNO>
	<brief_summary>The regimen PLD plus cyclophosphamide 4 cycle follow paclitaxel docetaxel 4 cycle ( noted phase II CAPRICE ) use experimental group . The regimen compare standard treatment doxorubicin plus cyclophosphamide ( AC ) 4 cycle follow paclitaxel docetaxel 4 cycle [ note National Comprehensive Cancer Network ( NCCN ) guideline ] .</brief_summary>
	<brief_title>Marched Pair Study Conventional Doxorubicin ( DOX ) Versus Pegylated Liposomal Doxorubicin ( PLD ) Neoadjuvant Chemotherapy</brief_title>
	<detailed_description>Purpose : Anthracycline base chemotherapy regimen milestone treatment breast cancer . A sequential protocol , use docetaxel Paclitaxel anthracycline-based combination primary treatment high-risk breast cancer .Despite efficient antitumor activity profile , use conventional anthracycline clinical practice limit due 's risk cardiac toxicity . The meta analysis show subclinical cardiotoxicity 17.9 % whereas incidence clinically overt cardiotoxicity 6.3 % . Overall cardiovascular event occur 10.6 % ( Lotrisone , Am J Cardiol . 2013 ) .Many patient heal breast cancer snatch life heart issue chemotherapy use anthracycline . There lot clinical trial explore possibility chemotherapy regimen without anthracycline , however recent result show anthracycline indispensible patient whose axillary node involve triple negative breast cancer ( ASCO 2016 ) .So target find kind anthracycline equal efficiency conventional anthracycline less cardiac toxicity . Pegylated Liposomal Doxorubicin ( PLD ) novel kind anthracycline . It distribute cardiac cell lowly release Doxorubicin ( DOX ) slow avoid peak plasma concentration , significant less cardiotoxicity compare free DOX . It also achieve non-inferior efficacy 50mg/m2 conventional anthracycline Metastatic Breast Cancer ( MBC ) . ( M. E. R. O'Brien , , Annals Oncology,2004 ; ) . PLD 35mg/m2 combination paclitaxel show overall response rate 71 % , tolerate toxicity skin ( 3 % hand-foot syndrome ) rare cardiac event ( H. Gogas1 , Annals Oncology , 2002 ; Gil-Gil , Breast Cancer Res Treat . 2015 ) However , There crucial question know 35mg/m2 PLD equivalent efficacy less cardiac toxicity compare 60 mg/m2 DOX adjuvant chemotherapy patient . The regimen PLD plus cyclophosphamide 4 cycle follow paclitaxel docetaxel 4 cycle ( noted phase II CAPRICE ) use experimental group . The regimen compare standard treatment doxorubicin plus cyclophosphamide ( AC ) 4 cycle follow paclitaxel docetaxel 4 cycle ( noted NCCN guideline ) . Condition Intervention Phase Individualized Chemotherapy Drug : Pegylated Liposomal Doxorubicin ( PLD ) Drug : Doxorubicin ( DOX ) Drug : Cyclophosphamide Drug : docetaxel Paclitaxel Phase 2 Study Type : Interventional Study Design : Allocation : assignment base patient desire Endpoint Classification : Safety/Efficacy Study Intervention Model : Marched pair Parallel Assignment Masking : Open Label Primary Purpose : Treatment</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pirarubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Patient histological proof invasive cancer , whose clinical tumor diameter &gt; 2 cm , &lt; 2 cm , Axillary lymphnodes involve .There metastatic Imaging finding . Stage II , III tumor , nonmetastatic , grade II III Performance Status = 01 World Health Organization ( WHO ) . Patient non pretreated breast cancer . Patient without cardiac pathology without anthracyclines contraindication ( assess normal ejection fraction ) . Normal haematological , renal hepatic function : platelet &gt; 100 . 109 /l , Hb &gt; 10 g/dl , normal bilirubin serum , Aspartate transaminase ( ASAT ) Alanine Aminotransferase ( ALAT ) &lt; 2,5 Upper Limit Normal ( ULN ) , alkaline phosphatase &lt; 2,5 ULN , creatinin &lt; 140 Âµmol/l creatinin clearance &gt; 60 ml/min Written inform consent date sign patient All breast cancer describe inclusion criterion , particular inflammatory and/or neglect ( T4b T4d ) form . Patient present intraduct cancer situ . ( DCIS ) Grade I well differentiate tumor . Non measurable lesion , two diameter , whatever radiological method use . Patient already operate breast cancer primary axillar node dissection . Patient present cancer system . Any psychological , familial , sociological geographical condition may potentially hamper compliance study protocol follow schedule , assess patient prior registration trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>Pegylated liposomal doxorubicin</keyword>
	<keyword>breast cancer</keyword>
</DOC>